secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0000950170-24-016804
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen gets FDA Fast Track for PGN-EDODM1 in DM1; Phase 1 data due 2024
-----------------------------------------------------------------------

- FDA granted Fast Track designation for PGN-EDODM1 targeting myotonic dystrophy type 1 (DM1).
- No approved therapies target root cause of DM1; PGN-EDODM1 aims to be disease-modifying.
- Ongoing FREEDOM-DM1 Phase 1 trial (NCT06204809); preliminary data expected in 2024.
- PGN-EDODM1 previously received FDA Orphan Drug Designation in September 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024016804/0000950170-24-016804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024016804/pepg-20240220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-016804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer